Quarterly ResultAug 6, 2026, 06:52 AM
Kenvue Q2 Net Sales +3.0% to $3.96B; Diluted EPS $0.24
AI Summary
Kenvue Inc. reported strong second-quarter 2026 financial results, with net sales increasing 3.0% to $3.96 billion and diluted EPS rising 9% to $0.24. The company achieved its third consecutive quarter of net and organic sales growth, with broad-based gains across all segments and regions. Kenvue also announced FDA approval for Tylenol with Naproxen and confirmed that its acquisition by Kimberly-Clark is expected to close in the fourth quarter of 2026.
Key Highlights
- Net sales increased 3.0% to $3.96 billion for Q2 2026.
- Organic sales grew 1.6%, marking the third consecutive quarter of growth.
- Diluted EPS rose 9% to $0.24; Adjusted Diluted EPS increased 7% to $0.31.
- FDA approved Tylenol with Naproxen, a new OTC fixed-dose combination.
- Acquisition by Kimberly-Clark is on track to close in Q4 2026.
- Self Care segment net sales increased 2.2% to $1.59 billion.
- Skin Health and Beauty segment net sales grew 5.1% to $1.11 billion.
- Free cash flow for the six months ended June 28, 2026, was $1.0 billion.
Price Impact
More from KVUE